Denali Therapeutics Inc. $DNLI Stake Increased by Aberdeen Group plc

Key Points

• Aberdeen Group plc boosted its stake in Denali by 82.6% in Q4 to 2,032,967 shares (about 1.39% of the company), valued at roughly $33.6 million; institutional ownership stands at ~92.9%.
• Other large investors piled in—Norges Bank initiated a ~$55.2M position and firms like Holocene Advisors and UBS significantly increased holdings—indicating substantial institutional accumulation.
• Stock and analyst outlook: Denali has a $3.27B market cap, posted a slight EPS beat last quarter (‑$0.73 vs. ‑$0.75), carries a consensus "Moderate Buy" rating with a $34.82 target, and has seen insider selling (including the CEO).

Aberdeen Group plc boosted its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 82.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,032,967 shares of the company's stock after acquiring an additional 919,381 shares during the period. Aberdeen Group plc owned 1.39% of Denali Therapeutics worth $33,564,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in DNLI. Norges Bank bought a new stake in shares of Denali Therapeutics in the 2nd quarter worth about $55,224,000. Holocene Advisors LP lifted its holdings in Denali Therapeutics by 677.8% during the 3rd quarter. Holocene Advisors LP now owns 3,135,712 shares of the company's stock worth $45,531,000 after buying an additional 2,732,540 shares during the last quarter. UBS Group AG grew its position in shares of Denali Therapeutics by 111.7% in the 3rd quarter. UBS Group AG now owns 2,012,353 shares of the company's stock worth $29,219,000 after acquiring an additional 1,061,589 shares in the last quarter. Foresite Capital Management VI LLC acquired a new position in shares of Denali Therapeutics in the 3rd quarter worth approximately $14,520,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Denali Therapeutics by 58.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company's stock valued at $22,732,000 after acquiring an additional 614,555 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI opened at $20.65 on Friday. The company has a market cap of $3.27 billion, a price-to-earnings ratio of -6.95 and a beta of 1.10. Denali Therapeutics Inc. has a 12-month low of $10.57 and a 12-month high of $23.77. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01. The stock's 50 day simple moving average is $20.49 and its 200 day simple moving average is $18.05.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.02. During the same period in the prior year, the company earned ($0.67) EPS. Equities research analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Jefferies Financial Group reissued a "buy" rating and set a $40.00 price target on shares of Denali Therapeutics in a research report on Monday, March 2nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Denali Therapeutics in a research note on Wednesday, January 21st. HC Wainwright increased their target price on shares of Denali Therapeutics from $32.00 to $42.00 and gave the stock a "buy" rating in a report on Thursday, March 26th. Robert W. Baird raised their price target on shares of Denali Therapeutics from $29.00 to $32.00 and gave the stock an "outperform" rating in a research report on Thursday, March 26th. Finally, Morgan Stanley lifted their price target on shares of Denali Therapeutics from $40.00 to $42.00 and gave the company an "overweight" rating in a report on Thursday, March 26th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Denali Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $34.82.

Insider Transactions at Denali Therapeutics

In related news, CEO Ryan J. Watts sold 35,198 shares of the stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $580,767.00. Following the sale, the chief executive officer owned 296,833 shares of the company's stock, valued at $4,897,744.50. This trade represents a 10.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alexander O. Schuth sold 17,218 shares of Denali Therapeutics stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $284,097.00. Following the completion of the sale, the insider owned 282,828 shares in the company, valued at approximately $4,666,662. This represents a 5.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 12.50% of the stock is owned by company insiders.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.